These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications. Hermida RC; Ayala DE; Mojón A; Fernández JR Chronobiol Int; 2013 Mar; 30(1-2):315-27. PubMed ID: 23181712 [TBL] [Abstract][Full Text] [Related]
10. Influence of age and hypertension treatment-time on ambulatory blood pressure in hypertensive patients. Hermida RC; Ayala DE; Crespo JJ; Mojón A; Chayán L; Fontao MJ; Fernández JR Chronobiol Int; 2013 Mar; 30(1-2):176-91. PubMed ID: 23077974 [TBL] [Abstract][Full Text] [Related]
11. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Hermida RC; Ayala DE; Mojón A; Fernández JR Chronobiol Int; 2010 Sep; 27(8):1629-51. PubMed ID: 20854139 [TBL] [Abstract][Full Text] [Related]
12. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Hermida RC; Ayala DE; Mojón A; Fontao MJ; Fernández JR Chronobiol Int; 2011 Aug; 28(7):601-10. PubMed ID: 21823969 [TBL] [Abstract][Full Text] [Related]
13. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. Hermida RC; Ayala DE; Fontao MJ; Mojón A; Fernández JR Chronobiol Int; 2010 Jul; 27(6):1287-303. PubMed ID: 20653455 [TBL] [Abstract][Full Text] [Related]
14. Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks. Hermida RC; Ayala DE; Smolensky MH; Fernández JR; Mojón A; Portaluppi F Hypertens Res; 2016 May; 39(5):277-92. PubMed ID: 26657008 [TBL] [Abstract][Full Text] [Related]
15. Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction. Hermida RC; Ayala DE; Fernández JR; Mojón A Chronobiol Int; 2013 Mar; 30(1-2):68-86. PubMed ID: 23181592 [TBL] [Abstract][Full Text] [Related]
16. Perspectives on the chronotherapy of hypertension based on the results of the MAPEC study. Portaluppi F; Smolensky MH Chronobiol Int; 2010 Sep; 27(8):1652-67. PubMed ID: 20854140 [TBL] [Abstract][Full Text] [Related]
17. Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Hermida RC; Ayala DE; Chayan L; Mojon A; Fernandez JR Chronobiol Int; 2009 Jan; 26(1):61-79. PubMed ID: 19142758 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring. Ríos MT; Domínguez-Sardiña M; Ayala DE; Gomara S; Sineiro E; Pousa L; Callejas PA; Fontao MJ; Fernández JR; Hermida RC; Chronobiol Int; 2013 Mar; 30(1-2):207-20. PubMed ID: 23077975 [TBL] [Abstract][Full Text] [Related]
19. Role of time-of-day of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk. Hermida RC; Ayala DE; Mojón A; Fernández JR Chronobiol Int; 2013 Mar; 30(1-2):328-39. PubMed ID: 23181738 [TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications. Ayala DE; Hermida RC; Mojón A; Fernández JR Chronobiol Int; 2013 Mar; 30(1-2):340-52. PubMed ID: 23077973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]